Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractor...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasra, Sakshi, Kazemi, Mohammed, Shah, Nishi, Chen, Jiahao, Fehn, Karen, Wang, Yanhua, Mantzaris, Ioannis, Kornblum, Noah, Sica, Alejandro, Bachier, LizaMarie, Goldfinger, Mendel, Gritsman, Kira, Braunschweig, Ira, Steidl, Ulrich, Shastri, Aditi, Verma, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784272/
https://www.ncbi.nlm.nih.gov/pubmed/33397455
http://dx.doi.org/10.1186/s40164-020-00186-y
Descripción
Sumario:Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.

Ejemplares similares